#VisualAbstract: Topical Delgocitinib Cream is Super to Oral Alitretinoin Capsules in Adults with Severe Chronic Hand Eczema
Click here to read this study in the Lancet. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: Eczema
Delgocitinib cream is effective and safe for the treatment of chronic hand eczema
1. More patients in the delgocitinib cream group reported clear or almost clear skin at week 16 in both the ...
#VisualAbstract: Twice-Daily Delgocitinib Cream was Effective for Adults with Moderate-to-Severe Chronic Hand Eczema
Click here to read this study in The Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
IL-23 inhibitors may have a lower risk of paradoxical eczema in comparison to other biologics
1. Interleukin-23 inhibitors had a lower risk of developing paradoxical eczema when treated for plaque psoriasis compared to TNF inhibitors, ...
Mental health disorders more prevalent amongst adults with inflammatory skin conditions
1. Anxiety and depression were more prevalent among individuals with eczema or psoriasis, and those with these inflammatory conditions were ...
Upadacitinib is safe and effective in adolescents with moderate-to-severe atopic dermatitis
1. Upadacitinib, a new once-daily oral systemic medication, reduces eczema severity and improves clinician- and patient-reported measures in adolescents with ...
Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
1. At week 16, all rocatinlimab groups reported significant improvements in eczema severity. 2. Most treatment-related adverse events were mild-to-moderate, ...
Dupilumab plus topical corticosteroids are effective in the treatment of childhood atopic dermatitis
1. By week 16, 28% of patients in dupilumab reported clear or almost clear skin (IGA 0-1) compared to 4% ...
Abrocitinib is more effective than dupilumab for treatment of moderate-to-severe atopic dermatitis
1. The co-primary endpoints at weeks 2 and 4 were significantly greater with abrocitinib than dupilumab. 2. Overall incidence of ...
